Trials / Recruiting
RecruitingNCT06815666
BAL Fluid Biomarkers in Sarcoma
Prospective Study of Biomarkers Derived From Bronchoalveolar Lavage Fluid to Predict Outcomes in Soft-Tissue Sarcomas
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Bronchoscopy & Metastasectomy | Routine bronchoscopy and standard of care metastasectomy |
Timeline
- Start date
- 2025-01-29
- Primary completion
- 2032-04-01
- Completion
- 2032-04-01
- First posted
- 2025-02-07
- Last updated
- 2026-03-04
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT06815666. Inclusion in this directory is not an endorsement.